MOTILIUM is contraindicated in the following situations: Known hypersensitivity to domperidone or any of the excipients.
Prolactin-releasing pituitary tumour (prolactinoma).
In patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure (see Warnings and Precautions).
co-administration with QT-prolonging drugs (see Interactions).
co-administration with potent CYP3A4 inhibitors (regardless of their QT-prolonging effects) (see Interactions).
Whenever stimulation of gastric motility might be dangerous, e.g., in the presence of gastro-intestinal haemorrhage, mechanical obstruction or perforation.
In patients with moderate or severe hepatic impairment (See Pharmacology: Pharmacokinetics under Actions).